RIL
TRVI icon

Rothschild Investment LLC’s Trevi Therapeutics TRVI Stock Holding History

Rothschild Investment LLC’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31K Hold
70
– – ﹤0.01% 2940
2026
Q1 		$835 Buy
+70
New +$784 ﹤0.01% 2945
2025
Q2 		– Sell
-40
Closed -$252 – 3188
2025
Q1 		$252 Buy
+40
New +$191 ﹤0.01% 2798

Other funds holding TRVI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Rothschild Investment LLC's TRVI Position: Q2 2026 in Review

Rothschild Investment LLC held its Trevi Therapeutics (TRVI) position steady in Q2 2026 at 70 shares worth $1.31K. The position accounts for ﹤0.01% of the portfolio, ranked #2940.

Rothschild Investment LLC first reported a position in TRVI in Q1 2025 and has held it in 3 quarters since. 69 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Rothschild Investment LLC held 70 shares of Trevi Therapeutics worth $1.31K as of Q2 2026.
  • Rothschild Investment LLC left its Trevi Therapeutics share count unchanged in Q2 2026.
  • Trevi Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #2940 holding.
  • Rothschild Investment LLC first reported a position in Trevi Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 69 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.